Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. News
Pliant Therapeutics, Inc. Quantitative Score
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Pliant Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Pliant Therapeutics, Inc. Financials
Table Compare
Compare PLRX metrics with: | |||
|---|---|---|---|
Earnings & Growth | PLRX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | PLRX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | PLRX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | PLRX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Pliant Therapeutics, Inc. Income
Pliant Therapeutics, Inc. Balance Sheet
Pliant Therapeutics, Inc. Cash Flow
Pliant Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Pliant Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Eric A. Lefebvre M.D. | Chief Medical Officer |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer |
| Mr. Johannes P. Hull J.D. | Chief Business Officer |
| Dr. Rik Derynck Ph.D. | Scientific Founder & Member of Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, Chief Executive Officer & Director | 1966 | 1.08M | |
| Dr. Eric A. Lefebvre M.D. | Chief Medical Officer | 1964 | 762.34K | |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer | 1977 | 713.07K | |
| Mr. Johannes P. Hull J.D. | Chief Business Officer | Male | 1975 | 654.52K |
| Dr. Rik Derynck Ph.D. | Scientific Founder & Member of Scientific Advisory Board | -- |
Pliant Therapeutics, Inc. Insider Trades
| Date | 23 Jan |
| Name | Cheung Lily |
| Role | Chief Human Resource Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 25875 |
| Date | 23 Jan |
| Name | Cheung Lily |
| Role | Chief Human Resource Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 51750 |
| Date | 23 Jan |
| Name | Ouimette Mike |
| Role | General Counsel & Corp. Sec'y |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 35000 |
| Date | 23 Jan |
| Name | Ouimette Mike |
| Role | General Counsel & Corp. Sec'y |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 70000 |
| Date | 23 Jan |
| Name | Hull Hans |
| Role | Chief Business Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40150 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 23 Jan | Cheung Lily | Chief Human Resource Officer | Acquired | A-Award | 25875 |
| 23 Jan | Cheung Lily | Chief Human Resource Officer | Acquired | A-Award | 51750 |
| 23 Jan | Ouimette Mike | General Counsel & Corp. Sec'y | Acquired | A-Award | 35000 |
| 23 Jan | Ouimette Mike | General Counsel & Corp. Sec'y | Acquired | A-Award | 70000 |
| 23 Jan | Hull Hans | Chief Business Officer | Acquired | A-Award | 40150 |